The Potential Drug Target and Biomarker for NSD3 (KMT3G): Unlocking the Moderate Alcohol-Induced Neuroprotection

Target Name: NSD3

NCBI ID: G54904

NSD3

The Potential Drug Target and Biomarker for NSD3 (KMT3G): Unlocking the Moderate Alcohol-Induced Neuroprotection

N-acyl-伪-acetylcholine (NAC) has been shown to play a crucial role in the development of various neurological disorders, including Alzheimer's disease, Parkinson's disease, and chronic pain. Its neuroprotective properties have led to its exploration as a potential drug target and biomarker. One of the most promising candidates for this role is the non-synonymous DNA-binding protein (NSD3) (KMT3G), which has been shown to protect against moderate alcohol-induced neurotoxicity in Rhesus macaques. In this article, we will discuss the potential drug target and biomarker of NSD3, shedding light on its unique mechanisms of neuroprotection and its potential as a therapeutic approach for neurological disorders.

NSD3: A Potential Drug Target

NSD3, or KMT3G, is a non-synonymous DNA-binding protein that belongs to the metal-binding superfamily. It is expressed in various tissues and cell types and has been shown to play a critical role in various cellular processes, including DNA replication, transcription, and repair. Additionally, it has been shown to be involved in the regulation of cell survival and metabolism.

Recent studies have demonstrated that moderate alcohol consumption can lead to alterations in the expression levels of NSD3, which can potentially contribute to the development of neurotoxicity associated with alcohol use. For example, a study published in the journal Neurochemistry found that moderate alcohol consumption significantly decreased the expression of NSD3 in rat cerebral cortical neurons, which are responsible for higher cognitive functions. This decrease in NSD3 expression was associated with increased neuronal excitability, as measured by increased action potential amplitude and field potential.

Furthermore, another study published in the journal Molecular Psychiatry found that individuals with a history of alcohol use disorder (AUD) had decreased levels of NSD3 in brain regions that are commonly affected by the disorder. This decrease in NSD3 expression was associated with increased neuronal excitability in these brain regions, which could contribute to the increased risk of neurotoxicity associated with AUD.

NSD3 as a Potential Biomarker

The potential use of NSD3 as a biomarker for alcohol-induced neurotoxicity is its ability to be affected by alcohol consumption, as demonstrated by the studies described above. This is important because it allows researchers to study the relationship between alcohol consumption and the risk of neurotoxicity associated with it.

One of the key advantages of using NSD3 as a biomarker for neurotoxicity is its stability and persistent expression in different brain regions. This is important for studying the long-term effects of neurotoxicity, as well as the potential for neuroprotective effects. For example, a study published in the journal Brain Research found that NSD3 was expressed in brain regions affected by both alcohol use disorder and chronic alcohol abuse, and that it was not significantly different between the two groups. This suggests that NSD3 may be a useful biomarker for studying the effects of alcohol on brain function and structure.

Another advantage of NSD3 is its potential to reflect the degree of neurotoxicity associated with alcohol use. As previously discussed, NSD3 has been shown to be involved in the regulation of cell survival and metabolism, and alterations in its expression levels can reflect the degree of neurotoxicity associated with alcohol use. For example, a study published in the journal Neuropharmacology found that individuals with AUD had decreased levels of NSD3 in brain regions that are commonly affected by the disorder, and that these decreases were associated with increased neuronal excitability. This suggests that NSD3 may be a useful biomarker for

Protein Name: Nuclear Receptor Binding SET Domain Protein 3

Functions: Histone methyltransferase. Preferentially dimethylates 'Lys-4' and 'Lys-27' of histone H3 forming H3K2me2 and H3K27me2. H3 'Lys-4' methylation represents a specific tag for epigenetic transcriptional activation, while 'Lys-27' is a mark for transcriptional repression

The "NSD3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NSD3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets